UK approves Wegovy pill, first daily GLP-1 weight-loss tablet in Europe
Oral semaglutide 25 mg has now cleared three regulators, and Novo says US prescriptions topped three million in just over five months.
DO
By Daniel Okafor · Regulatory Correspondent
Jun 15 03:00 ETSource: TradingView
The wire
- 01The UK authorized oral semaglutide 25 mg for chronic weight management in obese adults, the third approval after the United States and the UAE.
- 02Novo Nordisk reports more than three million US prescriptions since the early 2026 launch, with over 80% going to patients new to GLP-1 therapy, suggesting market expansion rather than switching.
- 03Novo still projects declines in 2026 sales and operating profit, citing US pricing pressure, softer injectable trends, reduced Medicaid obesity coverage and Lilly competition.
From the source
Read at tradingview.comNovo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
Novo Nordisk NVO shares have climbed 7% over the past week as investors responded to a series of favorable regulatory and commercial updates, reinforcing NVO’s position in the obesity market.